On January 10, 2023, Baylor Scott & White Research Institute, the research arm of Baylor Scott & White Health; the Translational Genomics Research Institute (TGen), part of City of Hope, a nonprofit biomedical research center; and OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, announced a new research study. This new, multi-year study will utilize Baylor Scott & White's Texas Immuno-Oncology Biorepository (TIOB)--which collects, catalogs, and stores samples of biological material for cancer research--to analyze resistance mechanisms in cancer using multi-omics tools including proteomics, single cell analysis, circulating tumor DNA (ct-DNA), and microbiome analysis combined with bioinformatics and machine learning tools. A comprehensive analysis will be conducted on lung cancer patients at various stages of the disease, analyzing elements such as the host response, the patient's microbiome, tumor DNA, and immune system activity. Testing will look at the patient's urine, blood, stool, tissue, cells, DNA, RNA, and proteins. The study will include some 350 patients who will receive follow-ups for up to five years.